XBIT Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (16 May 2024 @ 16:00):

Stats
Today's Volume	22 939.00
Average Volume	80 611.00
Market Cap	261.33M
EPS	$-0.329 ( 2024-05-10 )
Next earnings date	( $0 ) 2024-08-09
Last Dividend	$2.50 ( 2021-07-15 )
Next Dividend	$0 ( N/A )
P/E	-10.59
ATR14	$0.0610 (0.71%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-03	Simard John	Buy	2 470 355	Convertible Loan Agreement
2023-06-23	Waldin Jan-paul	Buy	25 000	Director Stock Option
2023-06-23	Libby Peter	Buy	25 000	Director Stock Option
2023-06-23	Macadam Donald H.	Buy	25 000	Director Stock Option
2023-06-23	Mckenzie W Thorpe	Buy	25 000	Director Stock Option

INSIDER POWER
98.00
Last 100 transactions
Buy: 4 116 188 \| Sell: 11 979 897

Volume Correlation

Long: 0.02 (neutral)

Short: 0.44 (neutral)

Signal:(51.49) Neutral

XBiotech Inc Correlation

10 Most Positive Correlations
GHRS	0.954
PVAL	0.953
LGACU	0.952
RAIL	0.952
MMYT	0.95
SWAV	0.948
HERAU	0.947
ABGI	0.944
KINS	0.944
LGAC	0.942

10 Most Negative Correlations
HCDIP	-0.953
RGC	-0.942
INFI	-0.936
SLGG	-0.936
BNRG	-0.935
AGRX	-0.934
VORB	-0.934
SGBX	-0.934
PRTS	-0.934
HNRG	-0.933

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

XBiotech Inc Correlation - Currency/Commodity

0.11
( neutral )

-0.12
( neutral )

0.00
( neutral )

-0.25
( neutral )

-0.35
( neutral )

0.21
( neutral )

XBiotech Inc Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-1.74M (0.00 %)
EPS:	$-0.810

FY	2023
Revenue:	$0
Gross Profit:	$-1.74M (0.00 %)
EPS:	$-0.810

FY	2022
Revenue:	$4.01M
Gross Profit:	$3.36M (83.77 %)
EPS:	$-1.080

FY	2021
Revenue:	$18.39M
Gross Profit:	$12.57M (68.36 %)
EPS:	$-0.580

Financial Reports:

No articles found.

XBiotech Inc Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

XBiotech Inc Dividend Information - No Dividend Player

Dividend Sustainability Score: 0.377 - low (50.00%) | Divividend Growth Potential Score: 0 - No dividend growth expected in the near future

Information

First Dividend	$2.50	2021-07-15
Last Dividend	$2.50	2021-07-15
Next Dividend	$0	N/A
Payout Date	2021-07-23
Next Payout Date	N/A
# dividends	1	--
Total Paid Out	$2.50	--
Avg. Dividend % Per Year	1.55%	--
Score	0.63	--
Div. Sustainability Score	0.377
Div.Growth Potential Score	0
Div. Directional Score	0	--

Next Divdend (Est)
(2024-05-17)

$0 Estimate 0.00 %

Dividend Stability

0.02 Very Bad

Dividend Score

0.63

Pay Frequency

Insufficient data to determine frequency

Yearly Payout

Year	Amount	Yield
2021	$2.50	15.50%
2022	$0	0.00%
2023	$0	0.00%
2024	$0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
OXLC	Dividend Diamond	2023-12-14	Monthly	14	10.00%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
OXSQ	Dividend Royal	2023-12-14	Monthly	21	9.10%	8.50
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
HRZN	Dividend Royal	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-11.73	1.500	-10.00	-10.00	[0 - 0.5]
returnOnAssetsTTM	-0.135	1.200	-4.50	-5.40	[0 - 0.3]
returnOnEquityTTM	-0.140	1.500	-2.66	-4.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	12.03	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	11.96	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	11.91	1.500	10.00	10.00	[0.2 - 2]
debtRatioTTM	0.0439	-1.500	9.27	-10.00	[0 - 0.6]
interestCoverageTTM	-12.52	1.000	-5.75	-5.75	[3 - 30]
operatingCashFlowPerShareTTM	-0.694	2.00	-0.231	-0.462	[0 - 30]
freeCashFlowPerShareTTM	-0.714	2.00	-0.357	-0.714	[0 - 20]
debtEquityRatioTTM	0.0478	-1.500	9.81	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.339	1.000	7.69	7.69	[0.2 - 0.8]
operatingProfitMarginTTM	-15.73	1.000	-10.00	-10.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-2.11	1.000	-10.00	-10.00	[0.2 - 2]
assetTurnoverTTM	0.0115	0.800	-3.26	-2.61	[0.5 - 2]
Total Score				0.377

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-8.52	1.000	-0.961	0	[1 - 100]
returnOnEquityTTM	-0.140	2.50	-1.713	-4.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	-0.714	2.00	-0.238	-0.714	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-0.694	2.00	-0.231	-0.462	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	-0.240	1.500	-4.94	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	-8.06	1.000	-10.00	0	[0.1 - 0.5]
Total Score				-2.36

XBiotech Inc Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

XBiotech Inc

XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation, and True Human COVID-19 therapy for treating the COVID-19 mutant virus. The company was incorporated in 2005 and is headquartered in Austin, Texas.